Description du projet
La gestion personnalisée à domicile de l’insuffisance rénale chronique
Les patients atteints d’insuffisance rénale chronique doivent surveiller leur fonction rénale, et ce, à long terme ou tout au long de leur vie, ce qui, en raison de la technologie impliquée, s’effectue toujours essentiellement à l’hôpital. Le projet CKDSens, financé par l’UE, entend améliorer les soins de santé actuels et proposer aux patients atteints d’insuffisance rénale chronique une prise en charge personnalisée de leur maladie. Le projet introduit une plateforme innovante sur le lieu d’intervention capable de réaliser un diagnostic précoce du dysfonctionnement du rein grâce à une surveillance quotidienne en temps réel des principaux biomarqueurs rénaux. En recourant à la décentralisation de l’analyse des biomarqueurs, les systèmes de diagnostic garantissent une gestion plus durable des ressources, tandis que les patients peuvent mener une vie plus active en bénéficiant du même traitement.
Objectif
Frequent monitoring of the renal function is required for hundreds of millions of people (90m in the EU): patients suffering from chronic kidney disease (CKD), diabetes and cardiovascular problems. The monitoring of these patients is still mostly done in hospitals, because the technology involved is too specialized to be handled by patients. Some companies offer limited qualitative monitoring in a near-patient care scenario, but quantitative monitoring is still centralized at hospitals. In this market, CDKSens can make a notable difference.
CreatSens, a technology-based company from Spain, is developing a new point-of-care platform for the personalized management of the kidney function. CKDSens aims to improve current healthcare by introducing new synthetic membranes to detect several relevant biomarkers. CKDSens is a low-cost innovation requiring little expertise, ideal in a near-patient care scenario. By decentralizing the biomarkers’ analysis with new diagnostic systems (i.e. moving it from the hospital to the patient’s home), healthcare professionals will waste less time and money on analyses. This helps sustain our healthcare system. Individual patients will be able to lead a more active life, while health inequalities get tackled along the way. Direct stakeholders are pharmaceutical companies, technological healthcare companies and foundations.
CreatSens wants to assess the technological and economic viability in the first 6 months (phase 1), to deliver a feasibility plan for phase 2 where the key steps for CreatSens to grow as a company in the European context will be introduced. CreatSens' 5-year growth plan is focused on selling the technology in 5 EU countries. We foresee 40 M€ turnover in the next 5 years, with the creation of 50 direct jobs and over 100 indirect jobs.
Champ scientifique
- medical and health sciencesclinical medicinecardiologycardiovascular diseasescardiac arrhythmia
- medical and health sciencesclinical medicineendocrinologydiabetesdiabetic nephropathy
- natural scienceschemical sciencesinorganic chemistryalkali metals
- engineering and technologymedical engineeringdiagnostic imagingcomputed tomography
- medical and health sciencesclinical medicinenephrologykidney diseases
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
43007 TARRAGONA
Espagne
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.